Trials / Completed
CompletedNCT01261741
Investigation of Memantine in the Treatment of Memory, Concentration or Attention Problems
Prospective, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Investigate the Efficacy and Safety of 10mg Memantine in the Treatment of Memory, Concentration or Attention Problems in the Absence of Dementia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 299 (actual)
- Sponsor
- Merz Pharmaceuticals GmbH · Industry
- Sex
- All
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
In this study, memantine will be tested in a new indication: in the treatment of subjective memory, concentration, or attention problems (subjective cognitive impairment) in the absence of dementia.
Conditions
- Memory Disorder
- Retention Disorder, Cognitive
- Subjective Cognitive Impairment
- Memory, Concentration or Attention Problems
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Memantine | Each subject will receive memantine 10mg tablets once daily |
| DRUG | Placebo | Each subject will receive matching placebo tablets once daily |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2011-08-01
- Completion
- 2011-09-01
- First posted
- 2010-12-16
- Last updated
- 2013-11-27
Locations
14 sites across 2 countries: Germany, United Kingdom
Source: ClinicalTrials.gov record NCT01261741. Inclusion in this directory is not an endorsement.